The Treatment Challenge of Hormone-Refractory Prostate Cancer
نویسندگان
چکیده
منابع مشابه
The treatment challenge of hormone-refractory prostate cancer.
BACKGROUND Both the demographics and treatment of hormone-refractory prostate cancer (HRPC) are changing. Patients are younger and healthier, with fewer comorbidities. The "no treatment until symptoms" approach is disappearing. Chemotherapy is increasingly being utilized. METHODS The authors review the steps involved in hormone management before chemotherapy is considered. The roles for chemo...
متن کاملSatraplatin in the treatment of hormone-refractory metastatic prostate cancer
Satraplatin is an orally bioavailable platinum chemotherapeutic agent under development for several cancer types, including hormone-refractory prostate cancer (HRPC). Satraplatin is being developed for the treatment of men with chemorefractory HRPC for several reasons: 1) relative ease of administration, 2) potential lack of cross-resistance with other platinum agents, 3) clinical benefits seen...
متن کاملHormone-refractory prostate cancer: choosing the appropriate treatment option.
Hormone-refractory prostate cancer (HRCaP) is both heterogeneous and lethal. Multiple treatment options exist, including secondary hormonal manipulations, chemotherapy, experimental options, and best supportive care. Choosing the appropriate therapy for an individual patient depends on several important clinical factors such as the presence or absence of symptomatic metastatic disease, age and ...
متن کاملAchieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
The belief that hormone-refractory prostate cancer (HRPC) is a chemotherapy-resistant disease has been effectively refuted by the results of two recent randomized phase III trials. The TAX327 trial compared weekly docetaxel, every-3-weeks (Q3W) docetaxel, and Q3W mitoxantrone plus prednisone in 1,006 patients with HRPC, and results demonstrated that survival was significantly longer with a doce...
متن کاملHormone-refractory prostate cancer: a shifting paradigm in treatment.
Prostate cancer, the most common male cancer, affects one in eight American men. Risk factors for the disease include increased age, race, and family history of prostate cancer. To date, surgery, radiation, and hormonal therapy have been the mainstays of treatment. In the past, chemotherapy served only a palliative role for men with prostate cancer and failed to produce a survival advantage or ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Control
سال: 2001
ISSN: 1073-2748,1073-2748
DOI: 10.1177/107327480100800603